← Back to Search

CAR T-cell Therapy

CAR T-Cell Therapy for Glioblastoma

Phase 1

Recruiting

Led By Lisa A Feldman

Research Sponsored by City of Hope Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Participant must have a Karnofsky performance status (KPS) >= 60

If participant has a ventriculoperitoneal shunt, the valve must be programmable, and must be able to tolerate their shunts being turned off for 48 hours

Must not have

Participant is unwilling to stop treatment with chemotherapy or endocrine therapy and/or radiation one week prior and during the first 4 cycles of the IL13Ralpha2-CAR T cell study

Research participant requires supplemental oxygen to keep saturation greater than 95% and the situation is not expected to resolve within 2 weeks

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 15 years

Awards & highlights

Summary

This trial is testing the effects of brain tumor-specific immune cells on patients with leptomeningeal disease from glioblastoma, ependymoma or medulloblastoma.

Who is the study for?

This trial is for patients with leptomeningeal disease from glioblastoma, ependymoma, or medulloblastoma. They must have a life expectancy of at least 8 weeks, be able to tolerate certain medical procedures and medications, not require dialysis or supplemental oxygen, and agree to use birth control. Those with other active cancers or infections like hepatitis B/C or HIV can't join.Check my eligibility

What is being tested?

The trial tests IL13Ralpha2-CAR T cells designed to target brain tumor-specific immune cells in patients with specific types of brain tumors that have spread. It's a phase I study focusing on the safety and how well these engineered immune cells work against the cancer.See study design

What are the potential side effects?

Potential side effects include reactions related to the immune system attacking normal tissues (autoimmune responses), infusion-related reactions where the treatment is given, changes in blood counts leading to increased infection risk or bleeding problems, fatigue, and possible unknown risks to fetuses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I can care for myself but may need occasional help.

Select...

My shunt valve is programmable and can be turned off for 48 hours.

Select...

My cancer has spread to the lining of my brain and spinal cord.

Select...

I have no allergies or adverse reactions to leukapheresis, steroids, or tocilizumab.

Select...

My tumor tests positive for IL13Ralpha2.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am willing to pause my current cancer treatments for the study.

Select...

I need extra oxygen to maintain my oxygen levels above 95%, and this won't improve in 2 weeks.

Select...

I have seizures that medication can't control or worsening brain function.

Select...

I have a bleeding disorder or cannot stop my blood thinner safely for a procedure.

Select...

I have a long-lasting or active virus infection in my brain or spinal cord.

Select...

I have another active cancer besides the one being studied.

Select...

I require dialysis.

Select...

I understand the study's purpose, procedures, and the risks/benefits of participating.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 15 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 15 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 15 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of adverse events

Secondary outcome measures

Biomathematical modeling of perfusion/diffusion

Neoplasms

CAR T and endogenous cells detected in tumor tissue

+8 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (IL13Ralpha2-CAR T cells)Experimental Treatment1 Intervention

Patients receive IL13Ralpha2-CAR T cells ICV over 5 minutes on day 1. Treatment repeats every 7 days for 4 cycles in the absence of disease progression or unacceptable toxicity.

0 / 13Eligibility criteria met

Find a Location

Who is running the clinical trial?

City of Hope Medical CenterLead Sponsor

575 Previous Clinical Trials

1,922,676 Total Patients Enrolled

3 Trials studying Ependymoma

38 Patients Enrolled for Ependymoma

National Cancer Institute (NCI)NIH

13,748 Previous Clinical Trials

40,959,371 Total Patients Enrolled

81 Trials studying Ependymoma

8,850 Patients Enrolled for Ependymoma

Lisa A FeldmanPrincipal InvestigatorCity of Hope Medical Center

Media Library

IL13Ralpha2-CAR T Cells (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04661384 — Phase 1

Ependymoma Research Study Groups: Treatment (IL13Ralpha2-CAR T cells)

Ependymoma Clinical Trial 2023: IL13Ralpha2-CAR T Cells Highlights & Side Effects. Trial Name: NCT04661384 — Phase 1

IL13Ralpha2-CAR T Cells (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04661384 — Phase 1

~8 spots leftby Nov 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.